Table of contents

Details Overview Explorer Related

Patent Term Extension Application from Novo Nordisk Inc. (on behalf of Novo Nordisk A/S)

FDA-2026-E-8226-0002Other

Comments

0

Awaiting comments

Deadline

--

Net supporti

—

Document

Details

The document's own metadata, straight from the source system.

Title: Patent Term Extension Application from Novo Nordisk Inc. (on behalf of Novo Nordisk A/S)

Posted: Jul 30, 2026
Comment period: Jul 30, 2026 – ?
Agency: Food and Drug Administration (FDA)
Topics: Intellectual Property
Pharmaceutical Policy

View on regulations.gov ↗

Analysis

Overview

No comments yet.

Comments

Explorer

Every mirrored comment — filter by stance, campaign, or issue.

Filter:

No comments match.